Elevance Health Raises Annual Profit Guidance
Elevance Health Inc (NYSE:ELV), previously known as Anthem Inc, has reported Q2 FY22 adjusted EPS of $8.04, up 14.4% Y/Y, beating…
EXCLUSIVE: Adial Pharma’s AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo.
Novavax’s COVID-19 Vaccine For Adults Gets CDC Advisory Committee Recommendation
The U.S. Centers for Disease Control and Prevention’s (CDC) advisory committee recommended using Novavax Inc’s (NASDAQ:NVAX) COVID-19 vaccine as a two-dose…
Recap of Tuesday’s Biotech Catalysts – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.
Belite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study
Belite Bio (NASDAQ: BLTE) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to support Phase 3 development of its lead asset LBS-008 for treatment of Stargardt Disease (STGD1).
Sorrento Shares Gain Following FDA’s Nod for Initial-Stage Covid-19 Study
Sorrento Therapeutics (NASDAQ: SRNE) announced that the U.S. Food and Drug Administration (FDA) has cleared the Phase 1 study of its candidate, STI-1558, in patients with impaired renal and hepatic function.
RBC Capital Lowers Inovio Price Target As It Awaits This
RBC Capital Markets has lowered the price target on Inovio Pharmaceuticals Inc (NASDAQ:INO) to $4 from $5 with a Sector Perform rating.…
JMP Is Bullish On This Cancer Stock “Sees New Way to Treat Cancer”
JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ:AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura…
Ultragenyx Shares Tumble On Initial Efficacy Missing Expectations, This Analyst Sees ‘Viable Path Forward”
Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients. The Overall CGI-C-AS…
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ:APLS) with a Buy rating and a $75 price target. The analyst expects Apellis’s…